Skip to content
Stock screener

PLRZ Polyrizon Ltd. stock chart & analysis

Conviction 28HealthcareScan · Fri, Nov 6, 2026

Polyrizon Ltd. (PLRZ) closed at $11.05 (-4.70%) on Nov 6, 2026. Price is above its 50-day and below its 200-day moving average. RSI(14) 63, RS Rating 98, -36.9% from its 52-week high, +35.2% year to date. Sector: Healthcare.

PLRZ$11.05-4.70%
ResistanceSupportVol 14
Loading chart…
Price11.05
Change-4.70%
Gap-1.21%
Rel volume0.10×
Avg volume25.4K
Avg $ vol260.62K
SMA 209.87
SMA 5010.54
SMA 20012.53
Price vs 50+8.96%
Price vs 200-8.38%
MA stackmixed
50/200 cross—
Supertrendup · 8.67
RSI (14)63
MACD hist0.34
MACD crossbull · 5d
Stoch %K / %D78 / 76
ADX (14)22
+DI / −DI33 / 12
RSI divergenceBullish
MACD divergenceBullish
ATR %8.16%
ADR %9.16%
52w high18.20
52w low2.88
From 52w high-36.92%
Above 52w low+298.61%
New 52w highNo
SqueezeOff
Bollinger width42.18%
%B0.89
Donchian pos80.18%
Donchian high12.34
Donchian low8.00
AVWAP (52w high)13.94
vs AVWAP high-17.65%
AVWAP (52w low)8.65
vs AVWAP low+32.66%
OBV trendUp
Chaikin MF (20)-0.05
Today vs 20d0.10×
Avg vol (14d)17.52K
Avg vol (20d)25.4K
Avg $ vol (20d)260.62K
Market cap18.46M
RS Rating98 / 99
RS 3m (vs SPY)+6.19%
RS 6m (vs SPY)-29.44%
RS line new highNo
Trend template3/8
Technical rank53.4
1 week+6.79%
1 month+29.43%
3 months+1.32%
6 months-29.74%
1 year+97.76%
YTD+35.22%
P/E—
P/B0.88
P/S—
P/FCF—
EPS—
Div yield—
ROE—
ROA—
Debt/Eq—
Current29.03
EV/EBITDA—
Gross margin—
Net margin—
Rev growth—
EPS growth—
Price target—
Target upside—
Analyst rating—
Institutional13.84%
Ent. value17.16M
Revenue—
Net income—
Gross profit—
Free cash flow—
Industry—
ExchangeNasdaq
Shares out2.08M
Employees1
ListedTue, Oct 29, 2024
Free float1.59M
Float %98.2%
Short interest—
Days to cover—
Short volume33.2%
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeD
Conviction28 / 100
Pattern quality—
Tech rank53.4 / 100
Group rank23 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance12.17
Support8.19
Days since event—
Candle confirm—

PLRZ technical analysis

Trend

PLRZ's moving averages are mixed — no clean uptrend or downtrend. It closed 9.0% above the 50-day ($10.54) and 8.4% below the 200-day ($12.53). ADX(14) at 22 points to a moderate trend. It meets 3 of 8 trend-template criteria.

Momentum

RSI(14) is 63, in the bullish half of its range. MACD crossed above its signal line 5 sessions ago. A bullish RSI divergence is in place. A bullish MACD divergence is in place. Its RS Rating of 98 puts its weighted 12-month performance ahead of about 98% of the US market.

Volume and volatility

Volume on the latest session ran 0.1× its 20-day average. It trades about $260,624 a day on average. ATR(14) is $0.9372, 8.2% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (-0.05) shows distribution.

Key levels

The chart pattern's support is $8.19 and its resistance $12.17. The 52-week range is $2.88 to $18.20; price is 36.9% below the high and 298.6% above the low. The VWAP anchored at the 52-week high is $13.94, above price.

Performance

PLRZ returned +6.8% (1 week), +29.4% (1 month), +1.3% (3 months), -29.7% (6 months), +97.8% (1 year), +35.2% (year to date).

About Polyrizon Ltd.

Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. The company's technology platforms are Capture & Contain and Trap & Target.

Listed 2024 · 1 employees

SEC filings

EDGAR filings in PLRZ · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.